Saccharomyces cerevisiae fungemia after probiotic treatment in an intensive care unit patient

Kara, İskender; Yıldırım, Fatma; Ozgen, Ozge; Erganiş, Sidre; Aydoğdu, Müge; Dizbay, Murat; Gürsel, Gül; Kalkancı, Ayşe

doi:10.1016/j.mycmed.2017.09.003

Cited by 35 publications

(32 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 2 of those 30 studies (corresponding to 1 article, Awad et al., ), the problem was due to a lack of information regarding the source attribution. In 19 studies (corresponding to 15 articles: Afsarian et al., ; Alobaid and Khan, ; Bharathi, ; Diba et al., ; Das et al., ; Hasan and Yassein, ; Jung et al., ; Kara et al., ; Khedri et al., ; Kaur et al., ; Nagy et al., ; Omran and Mansori, ; Sadrossadati et al., ; Shokohi et al., ; Teblick et al., ), the problem was due to predisposing factors in the exposed subject.…”

Section: Assessmentmentioning

confidence: 99%

“…For 32 of those 45 studies, no potential safety concern was reported, while a potential safety concern was described in the other 13 studies (corresponding to 11 articles: Diba et al, 2018;Das et al, 2018;Jung et al, 2018;Kara et al, 2018;Khedri et al, 2018;Afsarian et al, 2018;: 3 for C. famata (Das et al, 2018;Diba et al, 2018;, 7 for C. kefyr Diba et al, 2018;Khedri et al, 2018;, 1 for C. pelliculosa and 2 for Saccharomyces cerevisiae (Kara et al, 2018;. All these studies reported isolation of the QPS yeasts from opportunistic infections in patients with serious predisposing factors.…”

Section: Yeastsmentioning

confidence: 99%

“…These 30 articles included description of 45 studies related to different yeast species with QPS status, of which 16 referred to Candida kefyr (teleomorph = Kluyveromyces marxianus) Diba et al, 2018;Garc ıa-Agudo et al, 2018;Hasan and Yassein, 2018;Kaur et al, 2018;Khedri et al, 2018;Simi et al, 2019), 8 to Saccharomyces cerevisiae including Saccharomyces boulardii (corresponding to 7 articles: Lazo-V elez et al, Hasan and Yassein, 2018;Kara et al, 2018;, 10 to Candida famata (teleomorph = Debaryomyces hansenii) Cen et al, 2018;Das et al, 2018;Diba et al, 2018;Hasan and Yassein, 2018;Simi et al, 2019), 6 to Candida pelliculosa (synonymus = Pichia anomala, teleomorph = Wickerhamomyces anomalus) Cen et al, 2018;Jung et al, 2018;, 1 to Candida utilis (teleomorph = Lindnera jadinii) , 1 to Hanseniaspora uvarum , 1 Kluyveromyces lactis and 1 to Schizosaccharomyces pombe . One of these articles was considered relevant to evaluate since it presented new data on antimycotic MIC breakpoints for azoles but it is not associated to any specific yeast TU.…”

Section: Yeastsmentioning

confidence: 99%

“…In 2 of those 30 studies (corresponding to 1 article, , the problem was due to a lack of information regarding the source attribution. In 19 studies (corresponding to 15 articles: Afsarian et al, 2018;Diba et al, 2018;Das et al, 2018;Hasan and Yassein, 2018;Jung et al, 2018;Kara et al, 2018;Khedri et al, 2018;Kaur et al, 2018;, the problem was due to predisposing factors in the exposed subject.…”

Section: Yeastsmentioning

confidence: 99%

See 3 more Smart Citations

Update of the list of QPS‐recommended biological agents intentionally added to food or feed as notified to EFSA 10: Suitability of taxonomic units notified to EFSA until March 2019

Koutsoumanis¹,

Allende²,

Álvarez‐Ordóñez³

et al. 2019

EFS2

View full text Add to dashboard Cite

The qualified presumption of safety (QPS) procedure was developed to provide a harmonised generic preevaluation to support safety risk assessments of biological agents performed by EFSA's Scientific Panels. The taxonomic identity, body of knowledge, safety concerns and antimicrobial resistance were assessed. Safety concerns identified for a taxonomic unit (TU) are, where possible and reasonable in number, reflected by 'qualifications' which should be assessed at the strain level by the EFSA's Scientific Panels. During the current assessment, no new information was found that would change the previously recommended QPS TUs and their qualifications. The list of microorganisms notified to EFSA from applications for market authorisation was updated with 47 biological agents, received between October 2018 and March 2019. Of these, 19 already had QPS status, 20 were excluded from the QPS exercise by the previous QPS mandate (11 filamentous fungi) or from further evaluations within the current mandate (9 notifications of Escherichia coli). Sphingomonas elodea, Gluconobacter frateurii, Corynebacterium ammoniagenes, Corynebacterium casei, Burkholderia ubonensis, Phaeodactylum tricornutum, Microbacterium foliorum and Euglena gracilis were evaluated for the first time. Sphingomonas elodea cannot be assessed for a possible QPS recommendation because it is not a valid species. Corynebacterium ammoniagenes and Euglena gracilis can be recommended for the QPS list with the qualification 'for production purposes only'. The following TUs cannot be recommended for the QPS list: Burkholderia ubonensis, due to its potential and confirmed ability to generate biologically active compounds and limited of body of knowledge; Corynebacterium casei, Gluconobacter frateurii and Microbacterium foliorum, due to lack of body of knowledge; Phaeodactylum tricornutum, based on the lack of a safe history of use in the food chain and limited knowledge on its potential production of bioactive compounds with possible toxic effects.

show abstract

Section: Assessmentmentioning

confidence: 99%

Section: Yeastsmentioning

confidence: 99%

Section: Yeastsmentioning

confidence: 99%

Section: Yeastsmentioning

confidence: 99%

See 2 more Smart Citations

Update of the list of QPS‐recommended biological agents intentionally added to food or feed as notified to EFSA 10: Suitability of taxonomic units notified to EFSA until March 2019

Koutsoumanis¹,

Allende²,

Álvarez‐Ordóñez³

et al. 2019

EFS2

View full text Add to dashboard Cite

show abstract

“…The genus Saccharomyces is widespread yeast found in nature. This microorganism has been used as a probiotic agent in recent years (6). Saccharomyces boulardii , found in probiotic preparations, is now a strain of S. cerevisiae known as S. cerevisiae var.…”

Section: Introductionmentioning

confidence: 99%

Effect of microencapsulation on Saccharomyces cerevisiae var. boulardii viability in the gastrointestinal tract and level of some blood biochemical factors in wistar rats

Ghorbani-Choboghlo

Nikaein

Khosravi

et al. 2019

IJM

View full text Add to dashboard Cite

ABSTRACT Background and Objectives: Probiotics are live microorganisms that, when administered in an adequate amount, confer a health benefit on the host through the gut. Saccharomyces cerevisiae is a widespread yeast found in nature. This microor- ganism has been used as a probiotic agent in recent years. In this study, the effect of microencapsulation on survival rate of S. cerevisiae var. boulardii in the simulated gastrointestinal tract medium and the impact of microencapsulated S. cerevisiae var. boulardii on some serum biochemical factors in a rat model was evaluated. Materials and Methods: 30 male wistar rats were divided into three groups (control, rats receiving microencapsulated S. cerevisiae var. boulardii, and rats receiving S. cerevisiae var. boulardii alone). The probiotic was gavaged at a dosage of 2 gr/ kg BW for 8 weeks. Blood was collected from rats at the end of the treatment period and biochemical factors were measured using Mancompany kits. Results: The results showed a significant increase in viability of microencapsulated S. cerevisiae var. boulardii in compar- ison with free S. cerevisiae var. boulardii (p<0.05). Weight of rats in probiotic treated groups was significantly higher in comparison with the control group (p<0.05). Moreover, probiotic treatment reduced mean levels of triglycerides, cholesterol, free blood sugar and liver enzymes in rats. Conclusion: Microencapsulation could increase the survival rate of yeast probiotics in the gastrointestinal tract; however, more studies are needed for better understanding of the exact effect of microencapsulation on probiotics’ function.

show abstract

Species distribution and antifungal susceptibility profiles of yeasts isolated from onychomycosis: a cross-sectional study with insights into emerging species

Yazdanpanah,

Jabrodini,

Motamedi

et al. 2023

Antonie van Leeuwenhoek

View full text Add to dashboard Cite

Saccharomyces cerevisiae fungemia after probiotic treatment in an intensive care unit patient

Cited by 35 publications

References 30 publications

Update of the list of QPS‐recommended biological agents intentionally added to food or feed as notified to EFSA 10: Suitability of taxonomic units notified to EFSA until March 2019

Update of the list of QPS‐recommended biological agents intentionally added to food or feed as notified to EFSA 10: Suitability of taxonomic units notified to EFSA until March 2019

Effect of microencapsulation on Saccharomyces cerevisiae var. boulardii viability in the gastrointestinal tract and level of some blood biochemical factors in wistar rats

Species distribution and antifungal susceptibility profiles of yeasts isolated from onychomycosis: a cross-sectional study with insights into emerging species

Contact Info

Product

Resources

About